Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GIMEMA ALL 0394

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2019
2019
Most patients affected by Myelodysplastic syndromes (MDS) develop transfusion dependence, which can be correlated with poorer… Expand
2018
2018
Introduction: The phase 3 GIMEMA-MMY-3006 trial comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide… Expand
2015
2015
Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting… Expand
2015
2015
Introduction The introduction of novel agents in the treatment of Multiple Myeloma (MM) led to a significant improvement in the… Expand
2014
2014
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2014
2014
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
2013
2013
Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J… Expand
Highly Cited
2005
Highly Cited
2005
The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2004
2004
In the GIMEMA LAL 0496 trial, which has been conducted in Italy between 1996 and 2000, patients with adult ALL received an… Expand